BEAM THERAPEUTICS INC (BEAM) Stock News

NASDAQ:BEAM - Nasdaq - US07373V1052 - Common Stock - Currency: USD

18.11 -1.01 (-5.28%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BEAM Latest News, Press Relases and Analysis

All

Press Releases

2 hours ago - By: Zacks Investment Research - Mentions: CVAC

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

4 hours ago - By: Beam Therapeutics

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

4 hours ago - By: Beam Therapeutics

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

7 days ago - By: Zacks Investment Research - Mentions: CRSP

Will Beam Therapeutics Inc. (BEAM) Report Negative Q2 Earnings? What You Should Know

a month ago - By: Yahoo Finance

H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

a month ago - By: Yahoo Finance - Mentions: CERT INSP

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

a month ago - By: The Motley Fool - Mentions: TMDX PODD OPCH LFMD ...

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

a month ago - By: Benzinga - Mentions: COIN ESLT KTOS TSLA ...

Cathie Wood's Ark Invest Continues To Offload Coinbase, Bets Big On SoFi Technologies

2 months ago - By: Investor's Business Daily - Mentions: GILD CRSP SRPT LEGN ...

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

2 months ago - By: Benzinga - Mentions: LLY EDIT NTLA CRSP ...

Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

2 months ago - By: Investor's Business Daily - Mentions: LLY VERV NTLA EDIT ...

Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover

2 months ago - By: Yahoo Finance - Mentions: LLY VERV KHC NTLA

Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

2 months ago - By: Zacks Investment Research - Mentions: BMY

Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

2 months ago - By: Yahoo Finance - Mentions: DLTR NTLA SMCI NVDA

Biotech funding plummets as Trump policies unnerve investors: Jefferies

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

2 months ago - By: Yahoo Finance - Mentions: REVB ESLT CTKB KROS ...

Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering

2 months ago - By: Yahoo Finance - Mentions: VREX CTKB KROS CADL ...

Varex Imaging Corporation (VREX) Downgraded by S&P as Regulatory Outlook Remains Cloudy

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

2 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

3 months ago - By: Zacks Investment Research - Mentions: ILMN QURE NTLA CRSP ...

3 Top Genomics Stocks to Add to Your Portfolio in 2025

3 months ago - By: Beam Therapeutics

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

3 months ago - By: Beam Therapeutics

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

3 months ago - By: Beam Therapeutics

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

3 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

3 months ago - By: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

3 months ago - By: Zacks Investment Research - Mentions: SNY ADMA KYMR

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

3 months ago - By: Zacks Investment Research - Mentions: INSM ADPT ELEV

Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates

3 months ago - By: Zacks Investment Research - Mentions: REGN ANIP NTLA

Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up

3 months ago - By: Zacks Investment Research - Mentions: PCRX ADMA

Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

3 months ago - By: Zacks Investment Research - Mentions: ADMA RCKT

RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus

3 months ago - By: Zacks Investment Research - Mentions: SNY NVAX ADPT

NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up

3 months ago - By: Zacks Investment Research - Mentions: ADPT IOVA ELEV

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

3 months ago - By: Zacks Investment Research - Mentions: ADMA VTRS

Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains

3 months ago - By: Zacks Investment Research - Mentions: ANIP NTLA MIRM

Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised

3 months ago - By: Zacks Investment Research - Mentions: AMRN ANIP NTLA

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

3 months ago - By: Zacks Investment Research - Mentions: CPRX ADMA

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y

3 months ago - By: Zacks Investment Research - Mentions: ADMA APLS

Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down